share_log

ANI Pharmaceuticals (NASDAQ:ANIP) Rallies 5.6% This Week, Taking Three-year Gains to 35%

ANI Pharmaceuticals (NASDAQ:ANIP) Rallies 5.6% This Week, Taking Three-year Gains to 35%

ani pharmaceuticals(納斯達克:ANIP)本週上漲5.6%,爲期三年的漲幅達35%
Simply Wall St ·  11/09 22:08

By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at attractive prices, your portfolio returns could exceed the average market return. For example, the ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) share price is up 35% in the last three years, clearly besting the market return of around 16% (not including dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 18% in the last year.

通過購買指數基金,您可以輕鬆地與市場收益大致匹配。但如果您以有吸引力的價格購買優質業務,您的投資組合回報率可能會超過平均市場回報。例如,ANI Pharmaceuticals(納斯達克:ANIP)股價在過去三年中上漲了35%,明顯優於大約16%的市場回報率(不包括分紅)。然而,最近的回報並不像那樣令人印象深刻,該股票在過去一年僅上漲了18%。

Since it's been a strong week for ANI Pharmaceuticals shareholders, let's have a look at trend of the longer term fundamentals.

由於對ANI Pharmaceuticals股東來說,這是一個強勁的一週,讓我們來看一下長期基本面的趨勢。

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

市場有時毫無疑問是有效的,但股票價格並不總是反映基本業務表現。一種有缺陷但合理的方法是比較每股收益(EPS)和股票價格,以評估圍繞公司的情緒如何變化。

ANI Pharmaceuticals became profitable within the last three years. That would generally be considered a positive, so we'd expect the share price to be up.

ANI Pharmaceuticals在過去三年內實現了盈利。這通常被認爲是積極的,因此我們預期股價會上漲。

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

下圖顯示了EPS隨時間的變化情況(如果您單擊該圖像,則可以查看更多詳細信息)。

big
NasdaqGM:ANIP Earnings Per Share Growth November 9th 2024
納斯達克GM:ANI Pharmaceuticals每股收益增長2024年11月9日

It is of course excellent to see how ANI Pharmaceuticals has grown profits over the years, but the future is more important for shareholders. If you are thinking of buying or selling ANI Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.

看到ANI Pharmaceuticals多年來利潤增長當然是卓越的,但未來對股東來說更爲重要。如果您正在考慮買入或賣出ANI Pharmaceuticals股票,您應該查看這份免費的詳細報告以了解其資產負債表。

A Different Perspective

另一種看法

ANI Pharmaceuticals shareholders gained a total return of 18% during the year. But that was short of the market average. The silver lining is that the gain was actually better than the average annual return of 2% per year over five year. It is possible that returns will improve along with the business fundamentals. It's always interesting to track share price performance over the longer term. But to understand ANI Pharmaceuticals better, we need to consider many other factors. For instance, we've identified 2 warning signs for ANI Pharmaceuticals that you should be aware of.

ANI Pharmaceuticals股東在這一年總回報率爲18%。但這低於市場平均水平。好消息是收益實際上優於過去五年平均每年2%的年度回報率。隨着業務基本面的改善,回報可能會提高。長線追蹤股價表現總是很有趣。但要更好地了解ANI Pharmaceuticals,我們需要考慮許多其他因素。例如,我們已經發現了ANI Pharmaceuticals的2個警告信號,您應該注意。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

當然,您可能通過在其他地方尋找會找到一筆極好的投資。因此,請查看我們預計會增長收入的公司免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論